Grant: Proof of Principle Program - Phase I
McGill University
$160,000.00
Triple Targeted Kinase Inhibitors Capable of Inhibiting Breast Cancer Metastases
EF 2010-11
Résumé
Metastatic breast cancer is common in oncology practice and represents a major cause of morbidity and mortality in women with breast cancer. Despite a good progress in the discovery of novel targeted therapies, most metastatic breast cancers remain incurable with the best therapies available to-date. Therefore, novel therapies that selectively inhibit breast cancer progression to metastases are urgently needed. In this proposal, we aim to further validate and optimize the clinical efficacy of a novel class of experimental drugs (called benzisoselenazolone-derivatives), which we already identified to interfere with mechanisms that drives breast cancer progression to metastasis in experimental breast cancer models. The outcome of these studies will help us to consolidate our intellectual property and to translate quickly the best drug candidate into clinical applications for humans.
Programme
Proof of Principle Program - Phase I
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
227961
Name
Alaoui-Jamali Moulay A
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Proof of Principle
Projecttitle
Triple Targeted Kinase Inhibitors Capable of Inhibiting Breast Cancer Metastases
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$160,000
Cihrequipment2
$0
Programname2
Proof of Principle Program - Phase I
Keyworddelim
Breast Cancer; Investigational Drugs; Metastasis; Pharmacology; Preclinical Cancer Models; Structure-Activity
Abstract
Metastatic breast cancer is common in oncology practice and represents a major cause of morbidity and mortality in women with breast cancer. Despite a good progress in the discovery of novel targeted therapies, most metastatic breast cancers remain incurable with the best therapies available to-date. Therefore, novel therapies that selectively inhibit breast cancer progression to metastases are urgently needed. In this proposal, we aim to further validate and optimize the clinical efficacy of a novel class of experimental drugs (called benzisoselenazolone-derivatives), which we already identified to interfere with mechanisms that drives breast cancer progression to metastasis in experimental breast cancer models. The outcome of these studies will help us to consolidate our intellectual property and to translate quickly the best drug candidate into clinical applications for humans.
Competitiondate
201102
Approvedterm2
1 yr 0 mth
Pinamesdelim
Alaoui-Jamali, Moulay A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $160,000~ $0~